Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis

Gut

Volumn 62, Issue 12, 2013, Pages 1724-1733

  Kissow, Hannelouise ^a   Hartmann, Bolette ^a   Holst, Jens Juul ^a   Poulsen, Steen Seier ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIGESTIVE TRACT AGENT; EXENDIN (9-39); FLUOROURACIL; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE 2 [3-33]; LIRAGLUTIDE; NNC 103 0066; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DUODENUM; EPITHELIUM CELL; HEALING; HISTOLOGY; IATROGENIC DISEASE; INTESTINE INJURY; INTESTINE PARAMETERS; INTESTINE VILLUS; INTESTINE VILLUS HEIGHT; INTESTINE WEIGHT; JEJUNUM; MALE; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; SCORING SYSTEM; STOMACH PROTECTION; TREATMENT OUTCOME;

CHEMOTHERAPY; GASTROINTESTINAL PEPTIDES; GUT HORMONES; MUCOSAL INJURY; MUCOSAL REPAIR;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; FLUOROURACIL; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; INTESTINAL DISEASES; INTESTINAL MUCOSA; MALE; MICE; MUCOSITIS; PEPTIDE FRAGMENTS; RATS, WISTAR;

EID: 84887442572     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-303280     Document Type: Article

References (33)

1. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002;122:531-44.
2. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 2001;61:687-93.
3. Tavakkolizadeh A, Shen R, Abraham P, et al. Glucagonlike peptide 2 (glp-2) promotes intestinal recovery following chemotherapy-induced enteritis. Curr Surg 2000;57:502.
4. Iakoubov R, Lauffer LM, Trivedi S, et al. Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology 2009;150:4033-43.
5. Thulesen J, Hartmann B, Hare KJ, et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 2004;53:1145-50.
6. Trivedi S, Wiber SC, El-Zimaity HM, et al. Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer. Am J Physiol Gastrointest Liver Physiol 2012;302:G840-9.
7. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39.
8. Simonsen L, Pilgaard S, Orskov C, et al. Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats. Am J Physiol Gastrointest Liver Physiol 2007;293:G288-95.
9. Kissow H, Hartmann B, Holst J, et al. Glucagon-like peptide-1 (GLP-1) receptor agonists or DPP-4 inhibition do not accelerate neoplasia in carcinogen treated mice. Regul Pept 2012;179:91-100.
10. Kissow H, Viby NE, Hartmann B, et al. Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine. Cancer Chemother Pharmacol 2012;70:39-48.
11. Thulesen J, Knudsen LB, Hartmann B, et al. The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regul Pept 2002;103:9-15.
12. Shin ED, Estall JL, Izzo A, et al. Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology 2005;128:1340-53.
13. Nelson DW, Murali SG, Liu X, et al. Insulin-like growth factor I and glucagon-like peptide-2 responses to fasting followed by controlled or ad libitum refeeding in rats. Am J Physiol Regul Integr Comp Physiol 2008;294:R1175-84.
14. Goke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993;268:19650-5.
15. Hartmann B, Johnsen AH, Orskov C, et al. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 2000;21:73-80.
16. Ugleholdt R, Zhu X, Deacon CF, et al. Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1. Endocrinology 2004;145:1349-55.
17. Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta cell function. Diabetes 2011;60:1599-607.
18. Orskov C, Holst JJ, Poulsen SS, et al. Pancreatic and intestinal processing of proglucagon in man. Diabetologia 1987;30:874-81.
19. Howarth GS, Francis GL, Cool JC, et al. Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 1996;126:2519-30.
20. Sonis ST. A biological approach to mucositis. J Support Oncol 2004;2:21-32.
21. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004;4:277-84.
22. Logan RM, Stringer AM, Bowen JM, et al. Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 2008;7:1139-45.
23. Benjamin MA, McKay DM, Yang PC, et al. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 2000;47:112-19.
24. Booth C, Booth D, Williamson S, et al. Teduglutide ((Gly2) GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif 2004;37:385-400.
25. Prasad R, Alavi K, Schwartz MZ. Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. J Pediatr Surg 2000;35:357-9.
26. Prasad R, Alavi K, Schwartz MZ. GLP-2alpha accelerates recovery of mucosal absorptive function after intestinal ischemia/reperfusion. J Pediatr urg 2001;36:570-2.
27. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 1999;277(5 Pt 1):E937-47.
28. Alavi K, Schwartz MZ, Palazzo JP, et al. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg 2000;35:847-51.
29. Yamazaki K, Yasuda N, Inoue T, et al. The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight. Eur J Pharmacol 2004;488:213-18.
30. Rasmussen AR, Viby NE, Hare KJ, et al. The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin. Dig Dis Sci 2010;55:2785-96.
31. Cornu M, Yang JY, Jaccard E, et al. Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop. Diabetes 2009;58:1816-25.
32. Keefe DM, Sonis ST, Bowen JM. Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerging Drugs 2008;13:511-22.
33. Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, Placebo-controlled study. J Clin Oncol 2011;29:2808-14.